Concerns over vulnerable patients missing COVID-19 oral antivirals Patients in some areas are reportedly struggling to access treatments on the PBS in a timely way, even with a prescription.
Text reminders mooted for at-risk COVID-19 patients The Federal Health Minister has asked department officials for advice on ways of further raising awareness of oral antiviral treatments.
First real-world studies on COVID-19 oral antivirals emerge Pre-print studies are beginning to flesh out understanding of efficacy, suggesting Paxlovid may have a greater impact – particularly on at-risk older people.
Health officials flag increased use of antivirals as COVID becomes endemic The new oral treatments are likely to play a more central role in limiting the impact of COVID-19, but health authorities are still assessing how that will take shape.
Push for more detail on COVID-19 oral antivirals impact Experts highlight ‘crucial’ need for more understanding about how newly released oral antiviral drugs are performing in the broader population.
First COVID-19 antiviral receives PBS funding GPs can now prescribe molnupiravir for COVID-positive adult patients at risk of developing severe disease.
What GPs need to know about the new COVID antivirals Both oral antiviral COVID-19 treatments are now available, with significant restrictions, on the PBS.